Patrick OBrien - Arrowhead Pharmaceuticals General Counsel
| ARWR Stock | USD 22.12 0.25 1.14% |
Executive
Mr. Patrick C. OBrien is the General Counsel of Arrowhead Pharmaceuticals, Inc. Mr. OBrien joined the Company in December 2014. Mr. OBrien has practiced in the healthcare legal field for over 25 years. Before joining the Company, from 2012 to 2014, Mr. OBrien was with Shire, as global pharmaceutical company, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland Knight LLP in its Washington, DC office. In 2010, Mr. OBrien cofounded the law firm OBrien Gould PLLC which joined Holland Knight in 2011. From 2009 2010, Mr. OBrien was a partner in Burke ONeil LLC. From 2001 2009 Mr. OBrien served in several legal roles with Johnson Johnson, including serving as Vice President of Law for JJs Centocor OrthoBiotech unit. Mr. OBrien previously served as Regulatory Counsel with the United States Food Drug Administration since 2015.
| Age | 54 |
| Tenure | 9 years |
| Address | 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 |
| Phone | 626 304 3400 |
| Web | https://arrowheadpharma.com |
Arrowhead Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2466) % which means that it has lost $0.2466 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0624) %, meaning that it created substantial loss on money invested by shareholders. Arrowhead Pharmaceuticals' management efficiency ratios could be used to measure how well Arrowhead Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/29/2024, Return On Tangible Assets is likely to drop to -0.26. In addition to that, Return On Capital Employed is likely to drop to -0.32. At this time, Arrowhead Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 04/29/2024, Non Current Assets Total is likely to grow to about 790.5 M, while Other Assets are likely to drop slightly above 229.4 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jamie MD | AnnexonInc | 66 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| HsiuChiung Yang | Wave Life Sciences | N/A | |
| David Rodman | ProQR Therapeutics BV | N/A | |
| Linda JD | Wave Life Sciences | N/A | |
| Thomas Rollins | Assembly Biosciences | 68 | |
| Sarah Boyce | Ionis Pharmaceuticals | 45 | |
| Michael Panzara | Wave Life Sciences | 50 | |
| Rachel Humphrey | CytomX Therapeutics | 56 | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Traci McCarty | Biomarin Pharmaceutical | N/A | |
| Sarah Kiely | ProQR Therapeutics BV | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| PharmD MBA | Incyte | 66 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| Daryn Lewis | Wave Life Sciences | N/A | |
| Steven MD | Incyte | 57 | |
| Pamela Murphy | Incyte | 73 | |
| Gerard Platenburg | ProQR Therapeutics BV | 60 | |
| Miriam Mason | AnnexonInc | N/A | |
| Miguel Barbosa | Assembly Biosciences | N/A | |
Management Performance
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.25 |
Arrowhead Pharmaceuticals Leadership Team
Elected by the shareholders, the Arrowhead Pharmaceuticals' board of directors comprises two types of representatives: Arrowhead Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arrowhead. The board's role is to monitor Arrowhead Pharmaceuticals' management team and ensure that shareholders' interests are well served. Arrowhead Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arrowhead Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Douglas Given, Chairman of the Board | ||
| Javier MD, Chief Officer | ||
| Charles McKenney, Independent Director | ||
| Zhen Li, Senior Vice President - Chemistry & Manufacturing | ||
| Vince Anzalone, IR Contact Officer | ||
| MBA MD, Chief Medicine | ||
| Michael Perry, Independent Director | ||
| Chad Rubin, IR Contact Officer | ||
| Tracie Oliver, Chief Officer | ||
| PharmD JD, COO Counsel | ||
| Nadia MBA, VP Treasurer | ||
| Patrick OBrien, General Counsel | ||
| William Waddill, Independent Director | ||
| Howard Lovy, Director Communications | ||
| Kenneth Myszkowski, Chief Officer | ||
| Susan Boynton, Vice President - Regulatory Affairs | ||
| Edward Frykman, Director, Chairman of Audit Committee, Member of Nomination Committee, Member of Compensation Committee, Director of Insert Therapeutics Inc, Director of Unidym, Director of Aonex and Director of Calando | ||
| Bruce MD, Chief Scientist | ||
| Vincent CFA, Head VP | ||
| Douglass Given, Director | ||
| Aaron Tan, Head Tax | ||
| Peter Leone, Vice President-Strategy & Program Management | ||
| Bruce Given, COO | ||
| Christopher Anzalone, CEO and President Director, CEO of Calando, CEO of Tego, CEO of Nantope, CEO of Leonardo and CEO of Ablaris Therapeutics | ||
| Mauro Ferrari, Scientific Advisor, Director, Member of Nomination Committee and Member of Compensation Committee | ||
| Mark Davis, Founder Calando | ||
| David Lewis, Chief Scientific Officer | ||
| Mark Seefeld, Head VP |
Arrowhead Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arrowhead Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.06 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.63) % | ||||
| Operating Margin | (38.45) % | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 123.9 M | ||||
| Shares Owned By Insiders | 4.40 % | ||||
| Shares Owned By Institutions | 67.24 % | ||||
| Number Of Shares Shorted | 8.87 M | ||||
| Price To Earning | 482.39 X |
Arrowhead Pharmaceuticals Investors Sentiment
The influence of Arrowhead Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Arrowhead. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Arrowhead Pharmaceuticals' public news can be used to forecast risks associated with an investment in Arrowhead. The trend in average sentiment can be used to explain how an investor holding Arrowhead can time the market purely based on public headlines and social activities around Arrowhead Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Arrowhead Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Arrowhead Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Arrowhead Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Arrowhead Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arrowhead Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arrowhead Pharmaceuticals' short interest history, or implied volatility extrapolated from Arrowhead Pharmaceuticals options trading.
Pair Trading with Arrowhead Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Arrowhead Stock
| 0.87 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.75 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.66 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Arrowhead Stock
| 0.79 | ACB | Aurora Cannabis Sell-off Trend | PairCorr |
| 0.76 | HCM | HUTCHMED DRC | PairCorr |
| 0.71 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.59 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.
The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Arrowhead Stock analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Arrowhead Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arrowhead Pharmaceuticals. If investors know Arrowhead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arrowhead Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.098 | Earnings Share (2.77) | Revenue Per Share 1.697 | Quarterly Revenue Growth (0.94) | Return On Assets (0.25) |
The market value of Arrowhead Pharmaceuticals is measured differently than its book value, which is the value of Arrowhead that is recorded on the company's balance sheet. Investors also form their own opinion of Arrowhead Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Arrowhead Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arrowhead Pharmaceuticals' market value can be influenced by many factors that don't directly affect Arrowhead Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arrowhead Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arrowhead Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arrowhead Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.